Arbutus Biopharma on Tuesday sued U.S. drugmaker Pfizer Inc and its German partner BioNTech SE in a New Jersey district court, claiming their mRNA COVID-19 vaccines infringe five of Arbutus' patents.
in the Delaware federal court last year, claiming the latter's mRNA COVID-19 vaccine also infringes its patents.
"Pfizer and BioNTech are aware that Arbutus Biopharma and Genevant Sciences have filed an action for infringement with respect to certain U.S. Patents," BioNTech told Reuters, and added that the companies would not comment on their legal strategy.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
The antiviral drug Paxlovid reduces the risk of getting long COVIDIt’s not a panacea, but it might be one of the things that can help. CovidIsNotOver COVID19 LongCovid Paxlovid
Read more »
Santa Clara County Relaxes COVID RulesStarting Monday, Santa Clara County plans to follow new state guidance on COVID rules. Among other changes, masks will no longer be required in high-risk and health care facilities including jails, homeless shelters and long-term care homes.
Read more »
Scientists Fear ‘Catastrophic’ COVID Combination With Another VirusScientists are calling for a universal vaccine after a Chinese study warned COVID could combine with the super-lethal MERS virus.
Read more »
COVID-19 and Drug-Resistant Superbugs Are a Frightening Combination🔄FROM THE ARCHIVE Antibiotic resistance is a threat that’s lurking in the shadow of the coronavirus pandemic.
Read more »
Santa Clara County relaxes covid rulesSanta Clara County is grappling with how to implement the latest COVID-19 changes, as the state lifts rules on masking and vaccinations in April.
Read more »
China's March factory activity falters as post-COVID bounce fadesChina's sprawling manufacturing sector, accounting for a third of the world's second-largest economy by value, lost momentum in March as weak export orders outweighed a jump in activity driven by a recent exit from restrictive COVID-19 policies.
Read more »